CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $179,934.48 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 2,998,908 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $0.06, for a total value of $179,934.48. Following the completion of the sale, the insider now directly owns 13,005,169 shares of the company’s stock, valued at $780,310.14. The trade was a 18.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Trading Down 18.5 %

NASDAQ CERO opened at $0.06 on Monday. The company has a fifty day moving average price of $0.13 and a 200-day moving average price of $0.21. CERo Therapeutics Holdings, Inc. has a 1 year low of $0.06 and a 1 year high of $12.80.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.